Beam Therapeutics is trying to rewrite a disease-causing mutation inside the liver. Its pivotal test has now begun
Beam Therapeutics has begun dosing in the global pivotal cohort of its BEAM-302 trial, advancing a one-time in vivo base-editing therapy that could address both lung and liver disease in people with severe alpha-1 antitrypsin deficiency.